1stOncology™: Cancer Intelligence Service – Page 6498 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

University Of Pennsylvania Receives $55 Million Gift To Study, Treat Hereditary Cancers

On September 22, 2022 The University of Pennsylvania reported that it has received a $55 million gift for the study and treatment of hereditary cancers. The gift, from Penn alumni Mindy and Jon Gray, will be used to establish the Basser Cancer Interception Institute, at the Basser Center for BRCA , part of Penn’s Abramson Cancer Center (Press release, The Gray Foundation, SEP 22, 2022, View Source [SID1234621360]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The goal of the Institute is to move up the timeline of cancer treatment, "intercepting" various forms of the disease when abnormal BRCA1/2 cells develop — rather than relying on standard treatments like surgery, radiation or chemotherapy after a cancer has been detected. In its announcement, the university said, "the Basser team will pioneer efforts ranging from drugs and immune-based approaches to intercept BRCA-related cancers to new methods of detecting cancer cells with biomarkers and artificial intelligence."

According to the National Cancer Institute, BRCA1 and BRCA2 are tumor suppressor genes that play a role in controlling or preventing cancer. An error or mutation in a BRCA1 or BRCA2 gene increases an individual’s cancer risks. The mutation can also be inherited by an individual’s children who then face increased cancer risks in adulthood.

Spectrum Pharmaceuticals Provides Update on Poziotinib Following FDA Oncologic Drugs Advisory Committee Meeting

On September 22, 2022 Spectrum Pharmaceuticals (NasdaqGS: SPPI) ("Spectrum" or the "Company"), a biopharmaceutical company focused on novel and targeted oncology therapies, reported that the U.S. Food and Drug Administration’s ("FDA") Oncologic Drugs Advisory Committee ("ODAC") met to review poziotinib for the treatment of patients with previously treated locally advanced or metastatic non-small cell lung cancer ("NSCLC") harboring HER2 exon 20 insertion mutations (Press release, Spectrum Pharmaceuticals, SEP 22, 2022, View Source [SID1234621359]). The committee voted 9-4 that the current benefits of poziotinib did not outweigh its risks.

"We are disappointed by the outcome of the ODAC meeting, as patients with NSCLC HER2 exon 20 insertion mutations are in need of additional effective and safe therapies," stated Tom Riga, President and Chief Executive Officer of Spectrum Pharmaceuticals. "We plan to carefully evaluate our options for this program as we approach the November 24, 2022, PDUFA date. We would like to thank lung cancer patients and their families, as well as investigators and their staff, for their support."

ODAC is an independent panel of experts that reviews and evaluates data concerning the efficacy and safety of marketed and investigational products for use in the treatment of cancer. The committee makes appropriate recommendations to the FDA, but these recommendations are not binding and the final decision regarding product approval will be made solely by the FDA.

About Poziotinib

Poziotinib is a novel, oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that inhibits the tyrosine kinase activity of EGFR as well as HER2 and HER4, which, in turn, leads to the inhibition of the proliferation of tumor cells that overexpress these receptors. Mutations or overexpression/amplification of EGFR family receptors have been associated with a number of different cancers, including non-small cell lung cancer (NSCLC), breast cancer, and gastric cancer. HER2 exon 20 insertion mutations are a rare subset accounting for approximately 2-4% in NSCLC. There is no approved therapy for either treatment-naïve or previously treated NSCLC with HER2 exon 20 insertion mutations. Spectrum Pharmaceuticals holds an exclusive license from Hanmi Pharmaceutical ("Hamni") to develop, manufacture, and commercialize poziotinib worldwide, excluding Korea and China. Poziotinib is currently being investigated by the Company and Hanmi in several mid-stage trials in multiple solid tumor indications.

Servier collaborates in the treatment of pancreatic cancer

On September 22, 2022 Servier and Oncodesign Precision Medicine (OPM) reported a collaborative research agreement, named ‘STarT Pancreas’, to identify and validate new therapeutic targets in Pancreatic Ductal Adenocarcinoma (Press release, Servier, SEP 22, 2022, View Source [SID1234621358]).

The three-year agreement between Oncodesign Precision Medicine (OPM) and Servier includes two steps: Co-construction of an AI analytical platform based on data generated in the OncoSNIPE clinical trial and identification of targets with this platform; then experimental validation of the pre-selected targets.

Dr. Walid S. Kamoun, Servier’s Director of R&D Oncology: "We are delighted to initiate this collaboration with OPM, and to contribute to the development of an AI-based data analysis solution that could enable us to identify new therapeutic targets in pancreatic ductal adenocarcinoma, a dreaded cancer increasing in industrialized countries. This partnership is in line with the Group’s strategy of making the fight against cancer one of its strategic priorities, targeting hard-to-treat cancers for which treatment options are limited."

Pancreatic cancer is considered as one of the most difficult cancers to treat, due to its insidious symptoms and high degree of malignancy leading to a high mortality rate.

SELLAS Life Sciences Announces Poster Presentation at the Society of Hematologic Oncology (SOHO) Annual Meeting

On September 22, 2022 SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS’’ or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, reported its upcoming poster presentation related to its highly selective CDK9 inhibitor, GFH009, at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) being held on September 28 through October 1, 2022, in Houston, Texas and virtually (Press release, Sellas Life Sciences, SEP 22, 2022, View Source [SID1234621357]).

The poster presentation characterizes the preclinical pharmacokinetic (PK) profiles of two different formulations of GFH009 maleate, pH 4.5 and pH 6.0.

Additional presentation details can be found below:

Title: "Pharmacokinetics and Bioequivalence of Two Formulations of GFH009 Maleate Injection in Sprague Dawley Rats"

Abstract #: AML-259

Date/Time: Wednesday, September 28, 2022 at 6:05 PM ET

Presenter: Dragan Cicic, MD, Senior Vice President, Clinical Development, of SELLAS

ReCode Therapeutics to Present at Jefferies Cell and Genetic Medicine Summit?

On September 22, 2022 ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, reported that David Lockhart, Ph.D, President and Chief Scientific Officer of ReCode Therapeutics, will present a company overview at 8:00 a.m. ET on Thursday, September 29, 2022 at the upcoming Jefferies Cell and Genetic Medicine Summit being held in New York, NY (Press release, ReCode Therapeutics, SEP 22, 2022, View Source;utm_medium=rss&utm_campaign=recode-therapeutics-to-present-at-jefferies-cell-and-genetic-medicine-summit [SID1234621356]).